MARKET

ERYP

ERYP

Erytech Pharma
NASDAQ

Real-time Quotes | Nasdaq Last Sale

5.88
-0.17
-2.81%
After Hours: 5.88 0 0.00% 19:19 09/24 EDT
OPEN
6.01
PREV CLOSE
6.05
HIGH
6.01
LOW
5.88
VOLUME
10.31K
TURNOVER
--
52 WEEK HIGH
13.00
52 WEEK LOW
4.100
MARKET CAP
117.92M
P/E (TTM)
-1.3948
1D
5D
1M
3M
1Y
5Y
ERYTECH Announces the Availability of its Half-Year Financial Report 2021
ERYTECH Announces the Availabilityof its Half-Year Financial Report 2021 Lyon (France) and Cambridge, MA (U.S.), Septembre 22, 2021 – ERYTECH Pharma (Nasdaq & Euronext: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by en...
GlobeNewswire · 3d ago
European ADRs Climb Higher in Wednesday Trading
MT Newswires · 3d ago
BRIEF-Erytech Pharma SA Files For Mixed Shelf Of Upto $300 Mln
reuters.com · 4d ago
European ADRs Move Higher in Tuesday Trading
MT Newswires · 4d ago
ERYTECH Provides Business Update and Reports Financial Results for the First Half of 2021
ERYTECH Provides Business Update and Reports Financial Results for the First Half of 2021 Conference call and webcast on Tuesday, September 21, 2021at 8:30am EDT / 2:30pm CET TRYbeCA-1 Phase 3 trial of eryaspase in second-line metastatic pancreatic cancer ...
GlobeNewswire · 5d ago
SDC, EDSA and APRE among pre market gainers
ZIVO Bioscience (NASDAQ:ZIVO) +175%. Verastem (NASDAQ:VSTM) +22% Oncology's VS-6766 + defactinib combo shows promising action in ovarian cancer study Edesa Biotech (NASDAQ:EDSA) +33% announces positive phase 2 data of its monoclonal antibody in
Seekingalpha · 5d ago
12 Health Care Stocks Moving In Monday's Pre-Market Session
 
Benzinga · 5d ago
Earnings Scheduled For September 20, 2021
  Companies Reporting Before The Bell • Cognyte Software (NASDAQ:CGNT) is expected to report quarterly earnings at $0.15 per share on revenue of $115.57 million.  
Benzinga · 5d ago
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of ERYP. Analyze the recent business situations of Erytech Pharma through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 3 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average ERYP stock price target is 17.60 with a high estimate of 22.31 and a low estimate of 12.89.
EPS
Institutional Holdings
Institutions: 7
Institutional Holdings: 2.14M
% Owned: 10.65%
Shares Outstanding: 20.06M
TypeInstitutionsShares
Increased
1
689.66K
New
2
6.90K
Decreased
0
0
Sold Out
1
11.34K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-2.13%
Pharmaceuticals & Medical Research
-1.02%
Key Executives
Chairman/Director
Jean-Paul Kress
Chief Executive Officer/Director
Gil Beyen
Chief Financial Officer/Chief Operating Officer
Eric Soyer
Chief Technology Officer
Stewart Craig
Other
Jerome Bailly
Other
Jean-Sebastien Cleiftie
Other
Iman El-Hariry
Director
Luc Dochez
Director
Martine George
Director
Melanie Rolli
Independent Director
Sven Andreasson
Independent Director
Philippe Archinard
Independent Director
Hilde Windels
No Data
About ERYP
Erytech Pharma SA, also known as ERYTECH Pharma, is a France-based biopharmaceutical company developing medicinal products mainly in oncology, hematology and immunology fields of business. The Company offers ESY-ASP (GRASPA), a medicinal product consisting of L-Asparaginase entrapped into human homologous red blood cells. The product is used for treatment of Acute Lymphoblastic Leukemia (ALL), a childhood cancer. The Company's technology is based on the use of human red blood cells (RBCs) to improve the pharmacokinetic (PK) and pharmacodynamic (PD) properties of therapeutic enzymes, for instance asparaginase. The enzyme can destroy asparagine and deprive cancer cells of an important nutrient for these cells, resulting in their death.

Webull offers kinds of Erytech Pharma SA (ADR) stock information, including NASDAQ:ERYP real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ERYP stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ERYP stock methods without spending real money on the virtual paper trading platform.